Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

August 2021

Contributo di una variante prevalente in Europa vicino a CD83 e di una variante prevalente in Asia orientale vicino a IL17RB al rischio di herpes zoster nel trattamento con tofacitinib: risultati delle meta-analisi dello studio sull'associazione a livello di genoma

Arthritis Rheumatol. 2021;73(7):1155–66

Bing N,

Zhou H,

Chen X,

Kochi Y,

Fujio K,

Zhang B,

Genetic analysis of tofacitinib-treated subjects with RA or PsO identified multiple loci associated with increased herpes zoster (HZ) risk.It is well known that HZ risk is elevated in subjects with RA compared with the general population, and that treatment with JAK inhibitors may result in increased risks compared with TNFi and other bDMARD treatments. To this end, Bing, et al. used genome-wide association studies to identify genetic factors associated with an increased risk/faster onset of HZ ...

Keywords:

December 2018

Sicurezza ed Efficacia di Baricitinib nei Pazienti Trattati con Farmaci Antireumatici Modificanti la Malattia Sintetici Convenzionali o Corticosteroidi

Arthritis Rheumatol 2018 DOI: 10. 1002/art.40780

Lee EB,

Hazra A,

Hodge J,

Wang L,

Choy E

Tofacitinib (TOF) treatment is associated with short-term transient increases in absolute lymphocyte counts (ALC), followed by a gradual decline to reach steady state by ~48 months. Changes in both ALC and lymphocyte subset counts (LSC) were reversible upon TOF discontinuation. Low ALC but not LSC were associated with an increased risk of serious infective episodes (SIEs) and herpes zoster (HZ). This data supported the treatment recommendations on ALC counts for starting and continuing therapy w...